Finch Therapeutics Group, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 3.88 million compared to USD 62.35 million a year ago. Basic loss per share from continuing operations was USD 2.41 compared to USD 39.19 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.433 USD | +11.95% | +62.82% | -60.30% |
May. 30 | Finch Therapeutics Group, Inc.(NasdaqGS:FNCH) dropped from S&P TMI Index | CI |
May. 27 | Finch Therapeutics Group, Inc.(OTCPK:FNCH) dropped from NASDAQ Composite Index | CI |
1st Jan change | Capi. | |
---|---|---|
-60.30% | 2.3M | |
+55.70% | 59.34B | |
+42.83% | 40.24B | |
-5.39% | 39.88B | |
-5.56% | 28.55B | |
+16.46% | 27.26B | |
-20.56% | 19.23B | |
+33.03% | 12.61B | |
+25.85% | 12.28B | |
+2.72% | 12.49B |
- Stock Market
- Equities
- FNCH Stock
- News Finch Therapeutics Group, Inc.
- Finch Therapeutics Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024